| 000 | 01459 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515071431.0 | ||
| 264 | 0 | _c20070821 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1533-7294 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFakata, Keri L | |
| 245 | 0 | 0 |
_aPeripheral opioid antagonists: a therapeutic advance for optimizing opioid gastrointestinal tolerability. _h[electronic resource] |
| 260 |
_bThe Journal of family practice _cJun 2007 |
||
| 300 |
_aS3-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAnalgesics, Opioid _xadverse effects |
| 650 | 0 | 4 |
_aCathartics _xtherapeutic use |
| 650 | 0 | 4 |
_aConstipation _xchemically induced |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEducation, Medical, Continuing |
| 650 | 0 | 4 |
_aFamily Practice _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGastrointestinal Motility _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aNarcotic Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aPain, Intractable _xdiagnosis |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCole, B Eliot | |
| 773 | 0 |
_tThe Journal of family practice _gvol. 56 _gno. 6 Suppl Peripheral _gp. S3-12 |
|
| 999 |
_c17082836 _d17082836 |
||